Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial - Concepedia

Concepedia

Publication | Open Access

Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial

DOI Full Paper Access

413

Citations

16

References

2023

Year

Rohit Loomba, Manal F. Abdelmalek, Matthew J. Armstrong, Maximilian Jara, Mette Skalshøi Kjær, Niels Krarup, Eric Lawitz, Vlad Ratziu, Arun J. Sanyal, Jörn M. Schattenberg,

The Lancet. Gastroenterology & hepatology

Placebo-controlled Phase 2HepatologyLiver PhysiologyPharmacologyPharmacotherapyLiver DiseaseFatty Liver DiseaseMedicineNon-alcoholic Steatohepatitis-related Cirrhosis

References

	Year	Citations

Page 1

Page 1